PIK3CA
Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
FDA Approves Genentech's Itovebi Combo for PIK3CA-Mutated Advanced Breast Cancer Patients
In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.
European Commission Approves AstraZeneca's Truqap With Faslodex in ER-Positive Breast Cancer
Truqap will be the first AKT inhibitor approved in Europe for patients with ER-positive breast cancers harboring PIK3CA, AKT1, and PTEN mutations.
AstraZeneca's Truqap Misses Primary Endpoint in Phase III Triple-Negative Breast Cancer Trial
A combination of Truqap and paclitaxel did not improve the overall survival of patients with advanced triple-negative breast cancer.
FDA Grants Priority Review to Genentech's Inavolisib NDA in Breast Cancer
The agency is slated to decide in November whether to approve the PI3Kα inhibitor as a first-line option for PIK3CA-mutated advanced breast cancer.